• Solitary Plasmacytoma0
• Newly Diagnosed3
• Recurrent / Refractory1
• Post Transplant / Maintenance1
• Amyloidosis0
• Transplant0
• Waldenstrom's0

• Protocols

• HO07403

  OPEN TO ACCRUAL

  Collection Protocol of Bone Marrow Tumor Cells and Stromal Cells from MM Patients
  
  

• UW21091

  OPEN TO ACCRUAL

  Ph 3 Study Comparing IberDd versus DVd in Subjects with RRMM
  
  

• UW22075

  OPEN TO ACCRUAL

  Ph 1b/2 of BGB-11417 in Monotherapy and in Combinations with Dexamethasone and Carfilzomib in R/R MM
  
  

• UW22089

  OPEN TO ACCRUAL

  Phase 2 Study of CART-ddBCMA in Patients with Relapsed or Refractory Multiple Myeloma
  
  

• UW23031

  OPEN TO ACCRUAL

  COMMANDER Trial (COMbination regimens in MM post AHCT to elimiNate MRD utilizing IbERdomide)
  
  

• UW23044

  OPEN TO ACCRUAL

  EAP for Cilta-Cel OOS in Multiple Myeloma
  
  

• UW23048

  OPEN TO ACCRUAL

  EAP For Nonconforming Lisocabtagene Maraleucel
  
  

• UW23059

  OPEN TO ACCRUAL

  EAP for Subjects Receiving Nonconforming Ide-Cel in Multiple Myeloma
  
  

• UW23134

  OPEN TO ACCRUAL

  DB Ph 3 eff and safety of belumosudil w CCS vs placebo w CCS in pts 12 yrs and up with cGVHD
  
  

• UW23139

  OPEN TO ACCRUAL

  Ph 2 Study of JNJ-68284528, a CAR-T Therapy Directed Against BCMA in Subjects with MM
  
  

• UW23143

  OPEN TO ACCRUAL

  A Phase 2 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with RRMM
  
  

• UW24024

  OPEN TO ACCRUAL

  MRD-Guided Sequential Therapy for Deep Response in NDMM (MASTER-2/MM 160)